Combinations of Hepatitis C Virus Inhibitors

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.

What is claimed is: 
     
         1 . A composition comprising a therapeutically effective amount of a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II), 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         2 . The composition of  claim 1  further comprising one or two additional compounds having anti-HCV activity. 
     
     
         3 . The composition of  claim 2  wherein at least one of the additional compounds is an interferon or a ribavirin. 
     
     
         4 . The composition of  claim 3  wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau. 
     
     
         5 . A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a composition of  claim 1 . 
     
     
         6 . The method of  claim 5  further comprising administering one or two additional compound having anti-HCV activity prior to, after or simultaneously with the composition of  claim 1 . 
     
     
         7 . The method of  claim 6  wherein at least one of the additional compounds is an interferon or a ribavirin. 
     
     
         8 . The method of  claim 7  wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau.